PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company, has announced its participation in the BTIG Virtual Biotechnology Conference. The company’s President and CEO, Frank Bedu-Addo, PhD, will engage in a fireside chat on Monday, August 5, 2024, at 10:00 a.m. ET.
PDS Biotech focuses on revolutionizing how the immune system targets and eliminates cancers, as well as developing vaccines for infectious diseases. Interested parties can arrange meetings with the PDS Biotech team through their BTIG representatives. After the event, a replay of the fireside chat will be accessible in the Investor Relations section of the company’s website at www.pdsbiotech.com.
PDS Biotechnology (Nasdaq: PDSB), un’azienda di immunoterapia in fase avanzata, ha annunciato la sua partecipazione al BTIG Virtual Biotechnology Conference. Il Presidente e CEO dell’azienda, Frank Bedu-Addo, PhD, parteciperà a una conversazione informale il Lunedì 5 Agosto 2024, alle 10:00 ET.
PDS Biotech si concentra sulla rivoluzione del modo in cui il sistema immunitario identifica ed elimina i tumori, oltre a sviluppare vaccini per le malattie infettive. Le parti interessate possono organizzare incontri con il team di PDS Biotech tramite i loro rappresentanti BTIG. Dopo l’evento, una registrazione della conversazione informale sarà accessibile nella sezione Relazioni con gli Investitori del sito web dell’azienda all’indirizzo www.pdsbiotech.com.
PDS Biotechnology (Nasdaq: PDSB), una empresa de inmunoterapia en etapa tardía, ha anunciado su participación en la BTIG Virtual Biotechnology Conference. El Presidente y CEO de la empresa, Frank Bedu-Addo, PhD, participará en una charla informal el Lunes, 5 de Agosto de 2024, a las 10:00 a.m. ET.
PDS Biotech se centra en revolucionar la forma en que el sistema inmunológico identifica y elimina los cánceres, así como en desarrollar vacunas para enfermedades infecciosas. Las partes interesadas pueden organizar reuniones con el equipo de PDS Biotech a través de sus representantes de BTIG. Después del evento, una repetición de la charla informal estará disponible en la sección de Relaciones con Inversionistas del sitio web de la empresa en www.pdsbiotech.com.
PDS Biotechnology (Nasdaq: PDSB), 말기 면역요법 회사가 BTIG 가상 생명공학 컨퍼런스에 참여한다고 발표했습니다. 회사의 대통령이자 CEO인 Frank Bedu-Addo, PhD가 2024년 8월 5일 월요일, 오전 10:00(ET)에 편안한 대화에 참여합니다.
PDS Biotech은 면역 체계가 암을 감지하고 제거하는 방식을 혁신하고, 감염 질환에 대한 백신을 개발하는 데 집중합니다. 관심 있는 당사자는 BTIG 대표를 통해 PDS Biotech 팀과 회의를 주선할 수 있습니다. 이벤트 후, 대화의 재생은 회사 웹사이트의 투자자 관계 섹션에서 www.pdsbiotech.com에서 접근 가능합니다.
PDS Biotechnology (Nasdaq: PDSB), une entreprise d’immunothérapie en phase avancée, a annoncé sa participation à la BTIG Virtual Biotechnology Conference. Le Président et CEO de l’entreprise, Frank Bedu-Addo, PhD, participera à une discussion informelle le Lundi 5 Août 2024, à 10h00 ET.
PDS Biotech se concentre sur la révolution de la façon dont le système immunitaire cible et élimine les cancers, ainsi que sur le développement de vaccins pour les maladies infectieuses. Les parties intéressées peuvent organiser des réunions avec l’équipe de PDS Biotech par l’intermédiaire de leurs représentants BTIG. Après l’événement, un enregistrement de la discussion informelle sera accessible dans la section Relations Investisseurs du site web de l’entreprise à l’adresse www.pdsbiotech.com.
PDS Biotechnology (Nasdaq: PDSB), ein Unternehmen der späten Phase der Immuntherapie, hat seine Teilnahme an der BTIG Virtual Biotechnology Conference bekannt gegeben. Der Präsident und CEO des Unternehmens, Frank Bedu-Addo, PhD, wird am Montag, den 5. August 2024, um 10:00 Uhr ET an einem informellen Gespräch teilnehmen.
PDS Biotech konzentriert sich darauf, die Art und Weise zu revolutionieren, wie das Immunsystem Krebs erkennt und eliminiert, sowie darauf, Impfstoffe gegen infektiöse Krankheiten zu entwickeln. Interessierte Parteien können über ihre BTIG-Vertreter Treffen mit dem PDS Biotech-Team vereinbaren. Nach der Veranstaltung wird eine Aufzeichnung des informellen Gesprächs im Bereich Investor Relations auf der Unternehmenswebsite unter www.pdsbiotech.com verfügbar sein.
07/29/2024 – 08:00 AM
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 5, 2024, at 10:00 a.m. ET.
If you are interested in meeting with the PDS Biotech team during the conference, please contact your BTIG representative.
Following the event, an archived replay of the fireside chat will be available in the Investor Relations section of the Company’s website at www.pdsbiotech.com.
About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. We believe that proof-of-concept long-term data have shown positive survival results and tumor shrinkage with these combinations and indicate favorable tolerability.
We believe that the novel investigational mechanisms of action of Versamune® HPV and the combination of Versamune® HPV and PDS01ADC have resulted in compelling results with potential to successfully disrupt a tumor’s internal defenses, while also generating potent, targeted killer T-cells to attack the tumor. We also believe that data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated the potential for both platforms and point to potential broad utility.
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.
Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com
Media Contact:
Gina Mangiaracina
6 Degrees
Phone +1 (917) 797-7904
Email: gmangiaracina@6degreespr.com
FAQ
When is PDS Biotech (PDSB) participating in the BTIG Virtual Biotechnology Conference?
PDS Biotech (PDSB) is participating in the BTIG Virtual Biotechnology Conference on Monday, August 5, 2024, at 10:00 a.m. ET.
Who will represent PDS Biotech (PDSB) at the BTIG Virtual Biotechnology Conference?
Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech (PDSB), will represent the company at the conference.
What type of presentation will PDS Biotech (PDSB) give at the BTIG Virtual Biotechnology Conference?
PDS Biotech (PDSB) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference.
How can investors access the replay of PDS Biotech’s (PDSB) fireside chat at the BTIG conference?
An archived replay of the fireside chat will be available in the Investor Relations section of PDS Biotech’s (PDSB) website at www.pdsbiotech.com after the event.
What is the main focus of PDS Biotechnology (PDSB)?
PDS Biotechnology (PDSB) is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and developing vaccines for infectious diseases.
